Navigation Links
LifeCare Hospitals of Wisconsin Unveils Center for Advanced Wound Healing
Date:2/8/2008

outcomes."

Opened in September of 2007, the 62-bed LifeCare Hospitals of Wisconsin is one of the few hospitals in the country designed and built exclusively for the treatment of medically complex and treatment resistant patients who require extended hospitalization, typically for more than 25 days. The facility is located on a 40-acre parcel of land adjacent to GE Healthcare's Diagnostic Imaging World Headquarters; it is approximately 25 minutes from downtown Milwaukee and 55 minutes from Madison.

In addition to the Center for Advanced Wound Healing, the 60,000-square foot, state-of-the-art hospital features private rooms, including four bariatric suites; 10-bed intensive care unit; in-house diagnostic services including CT scan; surgical suites - including a bariatric operating room - for both inpatient and outpatient surgery; designated multi-therapy gym for physical, occupational and speech therapies; in-house laboratory services; aggressive ventilator weaning program; medical and interventional pain management services; cardiac telemetry with mobile critical care monitoring; and a highly experienced nursing staff certified with Advanced Cardiac Life Support training. The facility is located off Hwy T and I-94 on Golf Road in Pewaukee. To learn more or to arrange for a tour, please contact Kathryn Borgardt at (414) 587-0152, or visit http://www.LifeCare-Hospitals.com.


'/>"/>
SOURCE LifeCare Hospitals of Wisconsin
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. LifeCare Holdings, Inc. Announces Third Quarter Results
2. Norwalk virus: Cruise ship illness challenging and costly to hospitals, too
3. RNs at Nine Catholic Healthcare West Hospitals Reach Agreement on New Master Pact
4. Hospitals Could Improve Outcomes for Patients and Save Millions According to Hill-Rom 10th Annual Pressure Ulcer Survey
5. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
6. Hospitals Agree to Pay Fees in Exchange for More Income, but Consumers in the Dark About What Theyll be Charged Under Nunez Plan
7. Memphis Hospitals announces debt tender offer
8. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
9. Michigan Hospitals Receive Governors Award
10. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
11. Medina General Hospital and University Hospitals Agree to Pursue Affiliation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)... study being presented at the American Society of ...20), may change treatment practice in about 25 per...s for proposed changes to the way colorectal cance...ional Cancer Institute (NCI) SEER population-based... III clinical trial data, shows that outcomes of p...
(Date:5/16/2008)... fibroids located just beneath the lining of the u...endometrial cavity after uterine artery embolizati...s, according to a new study. , The study includ...MRI examination before and after UAE. The study fo...% migrated to the endometrial cavity after UAE, sa...
(Date:5/16/2008)...Live Web Cast Scheduled for May 19 at 10:15 a.m. E...all/ - Response Biomedical,Corporation (TSX: RBM, ...hief Executive Officer, is scheduled to present at... Conference on Monday May 19th at 10:15 a.m.,EDT.,...lable on the Company,s,Web site at, http://www.res...
(Date:5/16/2008)...elp docs determine who would benefit most from che... May 16 (HealthDay News) -- A panel of 15 genes ma...on-small cell lung cancer will experience a recurr...erapy, a new study shows. , By extension, the ...with less aggressive forms of the cancer who would...
Breaking Medicine News(10 mins):Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3
...n assumption that the elderly patients who are dep...al intervention programs, till such time they come...lly leads them to being excluded from such interve... that there is no strong connection between depres...
...le outcome, when a nurse, nurses an urge to kill. ..., was convicted of murdering two patients // and c...eneral Hospital in Oxfordshire. The accused had in...dangerous doses of medicines that caused the patie...
...ion campaigns worth few million dollars do not cha...y and other resources, argue nurses //. Additional...s to treat patients and target at-risk groups rath... high-profile advertising pushes. The issue would...
...nistry of China has reported bird flu infection in...ymptoms of fever and pneumonia // on 1st April has... If the World Health Organization confirms the pre...mark the 17th human case of avian influenza in the...
Other Medicine News:Health News:Health Promotion Drives Waste Money, Claim Nurses 2
(Date:5/15/2008)...PPENZELL, Switzerland, May 15 /- Ergo...Food and Drug Administration (FDA) has,granted orp...t of pulmonary,arterial hypertension (PAH). Tergur...tal Phase II trial in Europe., "The FDA,s grant o...ourages and strengthens our development program by...
(Date:5/15/2008)...ONITA SPRINGS, Fla., May 15 /- Tigris...on of a Cooperative Research and,Development Agree...CI) to,collaborate on clinical and preclinical dev...Phase I development. AFP-464 is converted to,metab...p53 activation and,apoptosis., This is part of a ...
(Date:5/15/2008)...derable Opportunity Remains for an Antiplatelet Th...eeding than the Combination of Plavix/Iscover ...on Resources, WALTHAM, Mass., May 15 /PRNewswire/... research and advisory firms for pharmaceutical an... Lilly,s Effient offers,improvement in patient com...
(Date:5/15/2008)... Line Data Expected soon after CEA Trial data repo... -, SAN FRANCISCO, May 15 /PRNewswire-FirstCa... a biotechnology company focused on the developmen... disease, announced today that,it has completed pa...CS),study. The ACS study is one of three Phase 2 t...
Breaking Medicine Technology:Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Pharmasset Commences Dosing in 28 Day Combination Study of R7128 with Pegasys 28R 29 plus Copegus 28R 29 for Hepatitis C 430 1Pharmasset Commences Dosing in 28 Day Combination Study of R7128 with Pegasys 28R 29 plus Copegus 28R 29 for Hepatitis C 430 2Pharmasset Commences Dosing in 28 Day Combination Study of R7128 with Pegasys 28R 29 plus Copegus 28R 29 for Hepatitis C 430 3Pharmasset Commences Dosing in 28 Day Combination Study of R7128 with Pegasys 28R 29 plus Copegus 28R 29 for Hepatitis C 430 4Pharmasset Commences Dosing in 28 Day Combination Study of R7128 with Pegasys 28R 29 plus Copegus 28R 29 for Hepatitis C 430 5Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy 2713 1Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy 2713 2Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy 2713 3Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System 2711 1Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System 2711 2Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System 2711 3California Company Slings Mud for Breast Cancer Awareness 2709 1California Company Slings Mud for Breast Cancer Awareness 2709 2
...e-FirstCall/ -- A total,of 20 oral and poster pres...,s hepatitis products, including PEGINTRON(TM),(pe...P) combination,therapy for chronic hepatitis C vir...034), the company,s investigational oral HCV,prote...opment, will,be presented by leading researchers a...
...eated with,Exforge achieved recommended blood pres... mmHg in,systolic blood pressure observed in patie...ous monotherapy[1] , Nearly 70% of those with hig... and most require two or more,medications to achie...007 - Exforge®,a single-tablet combination of...
Other Medicine Technology:Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 2Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 3Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 4Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 5Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 6Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8
Features soft, low friction sheath that extends beyond the tip.
Facilitates intubation of tracheal tubes.
Disposable Aluminum Satin Finish E/T Stylette, Pediatric 11 1/2, 25/box.
Solid Copper Malleable with Adjustable Stop 14.75.
Medicine Products: